webex: https://uwhealth.webex.com/uwhealth/j.php?MTID=m3e0079841c164c924e50bf2b3a66aaaf

Goals:

  1. Describe invasive candidiasis and candidemia and traditional antifungal treatment agents
  2. Identify rezafungin as new antifungal agent for candidemia and its drug characteristics
  3. Summarize primary literature of new agent
  4. Describe rezafungin's place in therapy
  5. Identify the pathophysiology and etiology of JET
  6. Summarize guideline recommendations for the management of JET in postoperative pediatric patients 
  7. Identify and discuss proper dosing and monitoring strategies for the management of JET with IV sotalol 
  8. Identify SGLT2i mechanism of action, indications, benefits, and adverse events
  9. Summarize the evidence and literature supporting SGLT2i use in HFpEF
  10. Discuss new guideline recommendations for SGLT2i use in HFpEF

 

Session date: 
10/10/2023 - 1:00pm to 2:00pm CDT
Location: 
In-person and Virtually
Will be determined by room availability
600 Highland Ave
Madison, WI 53705
United States
See map: Google Maps
  • 1.00 ACPE Contact Hours - Pharmacist
  • 1.00 ACPE Contact Hours - Pharmacist Technician
  • 1.00 University of Wisconsin–Madison Continuing Education Hours
Add to calendar: 

Please login or register to take this course.
Discloser List CME Internal Report
Presenter(s): 
Nicholas Ebert
Taylor Lueder
Kane Carstens